Atara Biotherapeutics secures Series B funds

Drug development company Atara Biotherapeutics has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation and EcoR1 Capital joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates and Kleiner Perkins Caufield & Byers.

North AmericaUSBriefs